Expression Profiles of SnoN in Normal and Cancerous Human Tissues Support Its Tumor Suppressor Role in Human Cancer

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Jahchan, Nadine S ^a,c   Ouyang, Gaoliang ^b   Luo, Kunxin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b XIAMEN UNIVERSITY   (China)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53; SKI NOVEL PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CARCINOGENESIS; CARCINOGENICITY; CELL INFILTRATION; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM; EPITHELIUM CELL; ESOPHAGUS; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; OVARY; PANCREAS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STROMA; TUMOR MICROENVIRONMENT; UPREGULATION;

ADULT; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; PANCREAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873886167     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055794     Document Type: Article

References (31)

1. Boyer PL, Colmenares C, Stavnezer E, Hughes SH, (1993) Sequence and biological activity of chicken snoN cDNA clones. Oncogene 8: 457-466.
2. Nomura N, Sasamoto S, Ishii S, Date T, Matsui M, et al. (1989) Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res. 17: 5489-5500.
3. Pearson-White S, (1993) SnoI, a novel alternatively spliced isoform of the ski protooncogene homolog, sno. Nucleic Acids Res. 21: 4632-4638.
4. Pearson-White S, Crittenden R, (1997) Proto-oncogene Sno expression, alternative isoforms and immediate early serum response. Nucleic Acids Res 25: 2930-2937.
5. Deheuninck J, Luo K, (2009) Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Res 19: 47-57.
6. Jahchan NS, Luo K (2010) SnoN in mammalian development, function and diseases. Curr Opin Pharmacol.
7. Zhu Q, Krakowski AR, Dunham EE, Wang L, Bandyopadhyay A, et al. (2007) Dual role of SnoN in mammalian tumorigenesis. Mol Cell Biol 27: 324-339.
8. Jahchan NS, You YH, Muller WJ, Luo K, (2010) Transforming growth factor-beta regulator SnoN modulates mammary gland branching morphogenesis, postlactational involution, and mammary tumorigenesis. Cancer Res 70: 4204-4213.
9. Shinagawa T, Nomura T, Colmenares C, Ohira M, Nakagawara A, et al. (2001) Increased susceptibility to tumorigenesis of ski-deficient heterozygous mice. Oncogene 20: 8100-8108.
10. Pan D, Zhu Q, Luo K, (2009) SnoN functions as a tumour suppressor by inducing premature senescence. Embo J 28: 3500-3513.
11. Pelzer T, Lyons GE, Kim S, Moreadith RW, (1996) Cloning and characterization of the murine homolog of the sno proto-oncogene reveals a novel splice variant. Dev Dyn 205: 114-125.
12. Krakowski AR, Laboureau J, Mauviel A, Bissell MJ, Luo K, (2005) Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-beta signaling by sequestration of the Smad proteins. Proc Natl Acad Sci U S A 102: 12437-12442.
13. Zhang F, Lundin M, Ristimaki A, Heikkila P, Lundin J, et al. (2003) Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res 63: 5005-5010.
14. Akagi I, Miyashita M, Makino H, Nomura T, Hagiwara N, et al. (2008) SnoN overexpression is predictive of poor survival in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 15: 2965-2975.
15. Chia JA, Simms LA, Cozzi SJ, Young J, Jass JR, et al. (2006) SnoN expression is differently regulated in microsatellite unstable compared with microsatellite stable colorectal cancers. BMC Cancer 6: 252.
16. Imoto I, Pimkhaokham A, Fukuda Y, Yang ZQ, Shimada Y, et al. (2001) SNO is a probable target for gene amplification at 3q26 in squamous-cell carcinomas of the esophagus. Biochem Biophys Res Commun 286: 559-565.
17. Villanacci V, Bellone G, Battaglia E, Rossi E, Carbone A, et al. (2008) Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus. Hum Pathol 39: 403-409.
18. Zhang X, Egawa K, Xie Y, Ihn H, (2009) The expression of SnoN in normal human skin and cutaneous keratinous neoplasms. Int J Dermatol 48: 579-583.
19. Nanjundan M, Cheng KW, Zhang F, Lahad J, Kuo WL, et al. (2008) Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol 2: 164-181.
20. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, et al. (2007) Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67: 3074-3084.
21. Truty MJ, Urrutia R, (2007) Basics of TGF-beta and pancreatic cancer. Pancreatology: official journal of the International Association of Pancreatology 7: 423-435.
22. Bascom JL, Fata JE, Hirai Y, Sternlicht MD, Bissell MJ, (2005) Epimorphin overexpression in the mouse mammary gland promotes alveolar hyperplasia and mammary adenocarcinoma. Cancer Res 65: 8617-8621.
23. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
24. Goh AM, Coffill CR, Lane DP (2010) The role of mutant p53 in human cancer. J Pathol.
25. McAllister SS, Weinberg RA, (2010) Tumor-host interactions: a far-reaching relationship. J Clin Oncol 28: 4022-4028.
26. Cianci R, Pagliari D, Pietroni V, Landolfi R, Pandolfi F, (2010) Tissue infiltrating lymphocytes: the role of cytokines in their growth and differentiation. J Biol Regul Homeost Agents 24: 239-249.
27. Kenny PA, Lee GY, Bissell MJ, (2007) Targeting the tumor microenvironment. Front Biosci 12: 3468-3474.
28. DeNardo DG, Andreu P, Coussens LM, (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 29: 309-316.
29. Bierie B, Moses HL, (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520.
30. Bierie B, Moses HL, (2010) Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 21: 49-59.
31. Yang L, Pang Y, Moses HL, (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31: 220-227.